MedTrace Logo

A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury

NCT04836481 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2024-02-29

No results posted yet for this study

Summary

This study aims is to describe the pharmacokinetic properties of levetiracetam through measurement of serum concentrations in critically ill, severe traumatic brain injury patients.

Conditions

Interventions

OTHER

Serum Sample Collection

Each patient will have 5 serum samples collected for analysis after a minimum six consecutive doses. Patients receiving LEV8 will have sampled collected at hours 0.5, 1, 4, 6, and 8. Patients receiving LEV12 will have sampled collected at hours 0.5, 1, 4, 8, and 12.

Sponsors & Collaborators

  • American College of Clinical Pharmacy

    collaborator OTHER

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Sarah Schuman Harlan, PharmD · University of Cincinnati

  • Shaun Keegan, PharmD · University of Cincinnati

  • Carolyn Philpott, PharmD · University of Cincinnati

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-05-01
Completion
2023-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04836481 on ClinicalTrials.gov